Blueprint Medicines (BPMC) Earnings Date, Estimates & Call Transcripts → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) Free BPMC Stock Alerts $105.56 -0.80 (-0.75%) (As of 05/31/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateAug. 7EstimatedActual EPS (May. 2) -$1.32 Beat By $0.32 Consensus EPS (May. 2) -$1.64 Get Blueprint Medicines Earnings AlertsEnter your email address below to receive the latest news and earnings results for BPMC and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueBPMC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BPMC Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry Blueprint Medicines Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20243($1.89)($1.31)($1.67) Q2 20243($1.40)($0.88)($1.13) Q3 20243($1.25)($0.58)($0.90) Q4 20243($1.22)($0.34)($0.71) FY 202412($5.76)($3.11)($4.40) Q1 20252($0.97)($0.93)($0.95) Q2 20252($0.86)($0.75)($0.81) Q3 20252($0.71)($0.61)($0.66) Q4 20252($0.52)($0.43)($0.48) FY 20258($3.06)($2.72)($2.89) Q1 20261($0.37)($0.37)($0.37) BPMC Earnings Date and InformationBlueprint Medicines last posted its quarterly earnings results on May 2nd, 2024. The biotechnology company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.64) by $0.32. The company earned $96.12 million during the quarter, compared to analyst estimates of $82.58 million. Blueprint Medicines has generated ($4.81) earnings per share over the last year (($4.81) diluted earnings per share). Earnings for Blueprint Medicines are expected to grow in the coming year, from ($5.15) to ($2.07) per share. Blueprint Medicines has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 7th, 2024 based off prior year's report dates.Read More Blueprint Medicines Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/7/2024(Estimated)------- 5/2/2024Q1 2024($1.64)($1.32)+$0.32($4.04)$82.58 million$96.12 million2/15/2024Q4 2023($2.04)($1.82)+$0.22($1.82)$67.34 million$71.96 million 10/26/2023Q3 2023($2.39)($2.20)+$0.19($2.20)$50.66 million$56.57 million 8/2/2023Q2 2023($2.58)($2.19)+$0.39($2.19)$45.60 million$57.60 million 5/4/2023Q1 2023($2.66)($2.15)+$0.51($2.15)$41.85 million$63.29 million 2/16/2023Q4 2022($2.73)($2.65)+$0.08($2.65)$33.52 million$38.78 million Get the Latest News and Ratings for BPMC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. 11/1/2022Q3 2022($2.51)($2.23)+$0.28($2.23)$43.49 million$65.98 million8/2/2022Q2 2022($2.23)($2.68)($0.45)($2.68)$37.61 million$36.55 million 5/3/2022Q1 2022($1.79)($1.79)-($1.79)$39.98 million$62.70 million 2/16/2022Q4 2021($0.71)($0.99)($0.28)$3.42$104.14 million$107.00 million 10/27/2021Q3 2021($1.63)($2.00)($0.37)($2.00)$42.58 million$24.19 million 7/28/2021Q2 2021($1.77)($1.86)($0.09)($1.86)$28.57 million$27.30 million 4/28/2021Q1 2021($1.80)($1.72)+$0.08($1.72)$24.71 million$21.58 million 2/16/2021Q4 2020($1.57)($1.53)+$0.04($1.53)$34.49 million$34.11 million 11/3/2020Q3 2020$6.49$11.16+$4.67$11.16$627.42 million$745.10 million 7/30/2020Q2 2020($2.08)($2.28)($0.20)($2.28)$7.56 million$8.34 million 5/6/2020Q1 2020($2.08)($2.11)($0.03)($2.11)$5.57 million$6.20 million 2/13/2020Q4 2019($1.71)($1.35)+$0.36($1.35)$26.00 million$51.53 million 11/5/2019Q3 2019($2.19)($1.93)+$0.26($1.93)$2.85 million$9.14 million8/1/2019Q2 2019($1.92)($2.04)($0.12)($2.04)$1.39 million$5.11 million Blueprint Medicines Earnings - Frequently Asked Questions When is Blueprint Medicines's earnings date? Blueprint Medicines has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 7th, 2024 based off last year's report dates. Learn more on BPMC's earnings history. Did Blueprint Medicines beat their earnings estimates last quarter? In the previous quarter, Blueprint Medicines (NASDAQ:BPMC) reported ($1.32) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.64) by $0.32. Learn more on analysts' earnings estimate vs. BPMC's actual earnings. How much revenue does Blueprint Medicines generate each year? Blueprint Medicines (NASDAQ:BPMC) has a recorded annual revenue of $249.38 million. How much profit does Blueprint Medicines generate each year? Blueprint Medicines (NASDAQ:BPMC) has a recorded net income of -$506.98 million. BPMC has generated -$4.81 earnings per share over the last four quarters. What is Blueprint Medicines's EPS forecast for next year? Blueprint Medicines's earnings are expected to grow from ($5.15) per share to ($2.07) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Cytokinetics Earnings Jazz Pharmaceuticals Earnings Intra-Cellular Therapies Earnings Viking Therapeutics Earnings Ascendis Pharma A/S Earnings Organon & Co. Earnings BridgeBio Pharma Earnings Ionis Pharmaceuticals Earnings Cerevel Therapeutics Earnings Madrigal Pharmaceuticals Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Hormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry ShiftsAbercrombie & Fitch First Quarter Earnings Surge to New HeightsTD Bank Q2 Earnings: Record Highs and Regulatory HurdlesPDD Holdings Earnings Volatility Alerts Buyers Zoom Stock’s Earnings Volatility Picked Up a Lot of BuyersBaidu Stock Earnings Prove Ray Dalio Right about China? This page (NASDAQ:BPMC) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarGold Set to EXPLODE!Gold Safe ExchangeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTradeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.